Rimexolone
Rimexolone is a synthetic corticosteroid designed for ophthalmic use that exerts anti-inflammatory effects by binding to intracellular glucocorticoid receptors, inhibiting the transcription of pro-inflammatory mediators including cytokines, chemokines, and adhesion molecules. It is used as a topical ophthalmic suspension for the treatment of postoperative ocular inflammation and anterior uveitis.
Berat Molekul
370,5000 g/mol
LogP
3,50
TPSA
54,40 Ų
Lipinski RO5
Lulus
Mekanisme Kerja
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
InChI
InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1
Molecular Formula
C24H34O3
HBD / HBA
1 / 3
Ikatan yang Dapat Dirotasi
2
Atom Berat
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Rimexolone is a synthetic corticosteroid designed for ophthalmic use that exerts anti-inflammatory effects by binding to intracellular glucocorticoid receptors, inhibiting the transcription of pro-inflammatory mediators including cytokines, chemokines, and adhesion molecules. It is used as a topical ophthalmic suspension for the treatment of postoperative ocular inflammation and anterior uveitis.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Rimexolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200617. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311412. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rimexolone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rimexolone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rimexolone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rimexolone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rimexolone"></drugfyi-drug>